Efficacy and safety of linagliptin/metformin fixed-dose combination as initial therapy in drug-naive Asian patients with type 2 diabetes

被引：0
|
作者：
Gong, Y. [1 ]
Mu, Y. [2 ]
Fan, B. [3 ]
Hehnke, U. [1 ]
Pan, C. [2 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Boehringer Ingelheim China Investment Co Ltd, Shanghai, Peoples R China
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
807
引用
收藏
页码：S388 / S388
页数：1
相关论文
共 50 条
  • [21] Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug-naive subjects with type 2 diabetes
    Lewin, A.
    DeFronzo, R.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S346 - S347
  • [22] Efficacy and safety of initial therapy with linagliptin and pioglitazone fixed-dose combinations versus monotherapy with pioglitazone or linagliptin
    Weber-Born, S.
    Nauck, M.
    Patel, S.
    Kobe, M.
    Toorawa, R.
    Woerle, H-J.
    [J]. DIABETOLOGIA, 2014, 57 : S329 - S329
  • [23] Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
    Hu, Jingbo
    Zou, Ping
    Zhang, Shuo
    Zhou, Minzhi
    Tan, Xueying
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (18) : 2471 - 2477
  • [24] Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    Rosenstock, J.
    Rood, J.
    Cobitz, A.
    Biswas, N.
    Chou, H.
    Garber, A.
    [J]. DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 650 - 660
  • [25] Linagliptin fixed-dose combination with metformin is bioequivalent to free-pill combination therapy
    Buschke, Susanne
    Ring, Arne
    Friedrich, Christian
    Metzmann, Katrin
    Meinicke, Thomas
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E238 - E238
  • [26] Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes
    Rosenstock, Julio
    Chuck, Leonard
    Gonzalez-Ortiz, Manuel
    Merton, Kate
    Craig, Jagriti
    Capuano, George
    Qiu, Rong
    [J]. DIABETES CARE, 2016, 39 (03) : 353 - 362
  • [27] Efficacy and Safety of Initial Combination Therapy with Linagliptin and Pioglitazone in Patients with Inadequately Controlled Type 2 Diabetes
    Gomis, Ramon
    Espadero, Rosa-Maria
    Jones, Russell
    Woerle, Hans-Juergen
    Dugi, Klaus A.
    [J]. DIABETES, 2010, 59 : A150 - A150
  • [28] EFFECTS OF GEMIGLIPTIN VERSUS SITAGLIPTIN OR GLIMEPIRIDE ON GLYCEMIC VARIABILITY AS INITIAL COMBINATION THERAPY WITH METFORMIN IN DRUG-NAIVE PATIENTS WITH TYPE 2 DIABETES
    Park, S. E.
    Lee, B. -W.
    Kim, J. H.
    Jung, C. H.
    Lee, S. -H.
    Suh, S. H.
    Lee, W. J.
    Jang, Y. H.
    Kim, S. -H.
    Park, C. -Y.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S139 - S139
  • [29] Effects of gemigliptin versus sitagliptin or glimepiride on glycaemic variability as initial combination therapy with metformin in drug-naive patients with type 2 diabetes
    Lee, B. -W.
    Kim, J.
    Park, S.
    Jung, C.
    Lee, S. -H.
    Suh, S.
    Lee, W.
    Cho, J. -H.
    Jang, Y.
    Kim, S. -H.
    Park, C. -Y.
    [J]. DIABETOLOGIA, 2015, 58 : S387 - S387
  • [30] Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
    Reynolds, Jonathan K.
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2009, 2 : 127 - 134
12345